Evoke Pharma (EVOK)

$4.75 +0.10 (2.15%)
Market Cap 7.40M
Revenue (ttm) 10.25M
Net Income (ttm) -5.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -52.20%
Debt to Equity Ratio 0.00
Volume 12,800
Avg Vol 190,964
Day's Range N/A - N/A
Shares Out 1.56M
Stochastic %K 83%
Beta -0.10
Analysts Hold
Price Target $10.00

Company Profile

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was i...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 858 345 1494
Address:
420 Stevens Avenue, Suite 230, Solana Beach, United States
HateTradingStocks
HateTradingStocks Oct. 12 at 7:28 PM
$EVOK My mother said I’m a loser. So I always got that going for me if this investment doesn’t work out.
0 · Reply
StockFlips
StockFlips Oct. 4 at 3:27 PM
I’ve been studying this ticker and chart all morning over at $SOPA currently locked in some gains and re entered near AH close. Monday will tell… But this is no pump and dump, it maintained 45%+ gain all throughout after hours Friday with ‘no back to square one’ sell off, and it maintained price above VWAP! This could be a locked in squeeze. If this breaks over $2 Monday and maintains over $2 during trading hours, I will 100% average up. If it really starts moving I will 10x my position for an emotional anxiety driven multi day run. Straight up vertical. Reminds me of previous monsters like $AGMH $WLDS $BSLK $EVOK Millions to be made 🤑
1 · Reply
Alfred_Penny_worth
Alfred_Penny_worth Sep. 30 at 1:53 PM
$EVOK Oh, hell nah...
0 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 24 at 1:39 PM
$ATCH look at my calls .19 on $ATCH ran to $2 $DVLT .42 went to .80 watch $EVOK 1.5 million float more cash then cap sideways will send imo and hard
0 · Reply
Lizardbronsen
Lizardbronsen Sep. 23 at 7:52 PM
$DVLT $EVOK
0 · Reply
KingKory
KingKory Sep. 23 at 7:51 PM
$DVLT $EVOK
0 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 23 at 7:51 PM
$DVLT $EVOK $EVOK more cash then cap. $DVLT 2.0 baby 1 million float LOL
0 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 23 at 7:48 PM
$DVLT don’t ever doubt me….. watch $EVOK IMO EASY MONEY. WE BULL NEVER LIES SEE TOU AT $6 and $10
0 · Reply
ACInvestorBlog
ACInvestorBlog Sep. 23 at 7:06 PM
$EVOK adding.
1 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 23 at 7:01 PM
$DVLT I smell $1. Also watch $EVOK 1 million float more cash then cap will see $10
0 · Reply
Latest News on EVOK
Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year

Oct 3, 2025, 9:08 AM EDT - 23 days ago

Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year

MAI Capital Management Announces Strategic Partnership with Evoke Advisors

Aug 27, 2025, 9:30 AM EDT - 2 months ago

MAI Capital Management Announces Strategic Partnership with Evoke Advisors

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

Aug 21, 2025, 7:00 AM EDT - 2 months ago

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Aug 6, 2025, 6:30 AM EDT - 2 months ago

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

Jul 9, 2025, 8:16 AM EDT - 3 months ago

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 5 months ago

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

Apr 28, 2025, 8:30 AM EDT - 6 months ago

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 8:36 PM EDT - 8 months ago

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:02 PM EDT - 8 months ago

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

Mar 6, 2025, 8:30 AM EST - 8 months ago

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

Feb 24, 2025, 8:30 AM EST - 8 months ago

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

Dec 19, 2024, 8:30 AM EST - 11 months ago

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

Dec 3, 2024, 8:30 AM EST - 11 months ago

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience

Nov 14, 2024, 8:00 AM EST - 1 year ago

InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 1 year ago

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Evoke Pharma stock surges over 100%—here's why

Oct 28, 2024, 12:34 PM EDT - 1 year ago

Evoke Pharma stock surges over 100%—here's why

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

Oct 22, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Sep 19, 2024, 2:20 PM EDT - 1 year ago

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry

Sep 18, 2024, 4:00 PM EDT - 1 year ago

XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Sep 4, 2024, 9:20 AM EDT - 1 year ago

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Evoke Pharma, Inc. Announces Reverse Stock Split

Jul 30, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Announces Reverse Stock Split

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

May 16, 2024, 4:02 PM EDT - 1 year ago

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

Evoke Pharma Reports First Quarter 2024 Financial Results

May 14, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Reports First Quarter 2024 Financial Results

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Apr 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

Mar 21, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 9:33 PM EDT - 1 year ago

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Mar 7, 2024, 4:10 PM EST - 1 year ago

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Feb 14, 2024, 7:30 AM EST - 1 year ago

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Feb 9, 2024, 7:30 AM EST - 1 year ago

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management

Jan 29, 2024, 9:00 AM EST - 1 year ago

Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

Nov 27, 2023, 8:30 AM EST - 2 years ago

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Nov 14, 2023, 8:30 AM EST - 2 years ago

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Evoke Pharma Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 8:30 AM EST - 2 years ago

Evoke Pharma Reports Third Quarter 2023 Financial Results

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

Evoke Pharma Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Reports Second Quarter 2023 Financial Results

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

Jul 25, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment

Jun 14, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment

Evoke Pharma Reports First Quarter 2023 Financial Results

May 15, 2023, 4:05 PM EDT - 2 years ago

Evoke Pharma Reports First Quarter 2023 Financial Results

Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

May 9, 2023, 7:00 AM EDT - 2 years ago

Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

HateTradingStocks
HateTradingStocks Oct. 12 at 7:28 PM
$EVOK My mother said I’m a loser. So I always got that going for me if this investment doesn’t work out.
0 · Reply
StockFlips
StockFlips Oct. 4 at 3:27 PM
I’ve been studying this ticker and chart all morning over at $SOPA currently locked in some gains and re entered near AH close. Monday will tell… But this is no pump and dump, it maintained 45%+ gain all throughout after hours Friday with ‘no back to square one’ sell off, and it maintained price above VWAP! This could be a locked in squeeze. If this breaks over $2 Monday and maintains over $2 during trading hours, I will 100% average up. If it really starts moving I will 10x my position for an emotional anxiety driven multi day run. Straight up vertical. Reminds me of previous monsters like $AGMH $WLDS $BSLK $EVOK Millions to be made 🤑
1 · Reply
Alfred_Penny_worth
Alfred_Penny_worth Sep. 30 at 1:53 PM
$EVOK Oh, hell nah...
0 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 24 at 1:39 PM
$ATCH look at my calls .19 on $ATCH ran to $2 $DVLT .42 went to .80 watch $EVOK 1.5 million float more cash then cap sideways will send imo and hard
0 · Reply
Lizardbronsen
Lizardbronsen Sep. 23 at 7:52 PM
$DVLT $EVOK
0 · Reply
KingKory
KingKory Sep. 23 at 7:51 PM
$DVLT $EVOK
0 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 23 at 7:51 PM
$DVLT $EVOK $EVOK more cash then cap. $DVLT 2.0 baby 1 million float LOL
0 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 23 at 7:48 PM
$DVLT don’t ever doubt me….. watch $EVOK IMO EASY MONEY. WE BULL NEVER LIES SEE TOU AT $6 and $10
0 · Reply
ACInvestorBlog
ACInvestorBlog Sep. 23 at 7:06 PM
$EVOK adding.
1 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 23 at 7:01 PM
$DVLT I smell $1. Also watch $EVOK 1 million float more cash then cap will see $10
0 · Reply
Seczet
Seczet Sep. 23 at 6:30 PM
$EVOK in
0 · Reply
SENDITSTOCKZ
SENDITSTOCKZ Sep. 23 at 6:28 PM
$EVOK this looks great sideways as all fuck more cash then cap! probably $10
0 · Reply
ACInvestorBlog
ACInvestorBlog Sep. 23 at 5:29 PM
$EVOK has a few potential near-term catalysts based on recent financial guidance and reporting schedules, though nothing groundbreaking like a new regulatory approval appears on the horizon as of late September 2025. Trading below cash levels with a beautiful setup.
0 · Reply
WandaMcclain581
WandaMcclain581 Sep. 21 at 12:26 PM
$EVOK Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative.
0 · Reply
HateTradingStocks
HateTradingStocks Sep. 16 at 1:24 AM
$EVOK wen moon?
1 · Reply
Tradeforincome
Tradeforincome Sep. 13 at 4:53 PM
$EVOK Q the buyout rumors!
2 · Reply
Ja094387
Ja094387 Sep. 9 at 12:28 AM
$EVOK did i fuxk up
0 · Reply
HypnoTrader
HypnoTrader Sep. 8 at 8:56 PM
$EVOK Morgan Stanley sucks. The only thing worse then the company are the stocks that they buy.
0 · Reply
HypnoTrader
HypnoTrader Sep. 8 at 8:51 PM
$EVOK Morgan Stanley only bought these shares to make you buy them, cause they know this stock sucks and will file for bankruptcy soon....
1 · Reply
ACInvestorBlog
ACInvestorBlog Sep. 8 at 8:41 PM
$EVOK Form 13G Morgan Stanley 10.5% stake https://www.sec.gov/Archives/edgar/data/895421/000089542125000528/xslSCHEDULE_13G_X01/primary_doc.xml
1 · Reply
Rain9991
Rain9991 Sep. 7 at 7:59 PM
$EVOK @resist, PT $ 5.36, $7, $9, then 10-12 if news, surge, luck
0 · Reply
BioTechChap
BioTechChap Sep. 3 at 1:59 PM
$PHAT Not much talk about previously mentioned pipeline expansion/acquisitions today. Looks like $EVOK might be a suitable company to acquire. Anyone other thoughts?
1 · Reply